UroGen Pharma Ltd.
URGN
$9.87
-$0.27-2.66%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -32.70% | -24.09% | -9.78% | -4.16% | 6.53% |
| Total Depreciation and Amortization | -17.83% | -30.44% | -24.67% | -17.02% | -9.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.95% | 15.18% | 5.38% | 7.11% | -8.97% |
| Change in Net Operating Assets | 1,127.42% | 47.87% | -29.84% | 767.30% | 119.77% |
| Cash from Operations | -30.07% | -26.70% | -12.93% | -0.39% | 7.91% |
| Capital Expenditure | -98.25% | -52.06% | -56.29% | -17.65% | 32.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,024.14% | -2,576.94% | -374.42% | 776.08% | 207.52% |
| Cash from Investing | -1,054.63% | -2,062.96% | -376.36% | 708.48% | 200.46% |
| Total Debt Issued | -- | -- | -2.01% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -20.74% | 122.03% | 120.89% | 8,722.78% | 5,501.15% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -61.72% | -61.72% | -61.72% | 420,981.25% | 68,691.55% |
| Cash from Financing | -18.09% | 66.44% | 36.78% | 893.51% | 531.55% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -128.61% | 95.04% | -93.53% | 430.03% | 238.40% |